NCT05944783

Bioequivalence Studies of Dasatinib 100 Mg

Bioequivalence Studies of Dasatinib 100 Mg Tablets in Healthy Colombian Subjects in Postprandial Condition

• Status: Not Yet Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 46 (estimated)
• Sponsor: Centro de Atencion e Investigacion Medica · Network
• Sex: Male
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

A bioequivalence study of Dasatinib will be carried out in 46 healthy subjects, in fed condition, following the complete replicated design, randomized, comparative of 2 sequences, 2 study formulations, in a single dose of 100 mg of Dasatinib tablets / coated tablets, 4 periods. , with a washout time of 7 days between each dose

Detailed description

A bioequivalence study of Dasatinib in 46 healthy subjects, in fed condition, complete replicated design, comparative of 2 sequences, 2 formulations, single dose of 100 mg of Dasatinib tablets / coated tablets, 4 periods. , with a washout time of 7 days between each dose

Conditions

• Myeloma Multiple

Interventions

Type	Name	Description
DRUG	Dasatinib 100 MG	single dose of 100 mg Dasatinib tablets

Timeline

• Start date: 2025-09-01
• Primary completion: 2025-12-20
• Completion: 2026-04-30
• First posted: 2023-07-13
• Last updated: 2025-02-12

Locations

1 site across 1 country: Colombia